An immediate-release oxycodone hydrochloride formulation (IRO-A) indicated for moderate to severe pain was designed (by adding functional excipients) to discourage tampering associated with intranasal and intravenous abuse of prescription opioids.
The primary objective of this study was to determine the dose proportionality of oxycodone in IRO-A tablets under fasted conditions. Secondary objectives were to assess food effects on the pharmacokinetics of IRO-A tablets, to compare the relative bioavailability of oxycodone in IRO-A tablets versus marketed oxycodone hydrochloride (IRO) tablets under fed conditions and to evaluate the single-dose safety profile of the IRO-A tablets in healthy volunteers pretreated with naltrexone.
This open-label, single-dose, randomized, 5-way crossover study was conducted in healthy adults who received each of the following treatments, separated by a washout period of ≥7 days: IRO-A 1 × 5 mg, 2 × 5 mg, and 2 × 7.5 mg under fasted conditions, and IRO-A 2 × 7.5 mg and IRO 1 × 15 mg after a high-fat, high-calorie breakfast. Naltrexone was administered to minimize untoward pharmacologic effects of oxycodone. Dose proportionality (IRO-A), food effects (IRO-A), and relative bioavailability in a fed state (IRO-A and IRO) were assessed by using bioequivalence criteria (90% CIs between 80% and 125% for Cmax and AUC).
Of the 35 adults enrolled in the study, 33 completed at least 1 dosing period. Most participants were male (54%) and white (69%), with a mean (SD) age of 32.6 (11.1) years and mean weight of 75.5 (12.3) kg. Plasma levels of oxycodone in IRO-A suggested dose-proportional pharmacokinetics; 90% CIs for dose-normalized Cmax, AUC0–last, and AUC0–∞ fell within the 80% to 125% range. Concomitant food intake with IRO-A resulted in an ∼14% reduction in oxycodone Cmax and an ∼21% increase in AUC0–last. The bioavailability of oxycodone from IRO-A tablets in the fed state was comparable with IRO tablets based on AUC parameters, although Cmax was ∼16.5% lower. Reported or observed treatment-emergent adverse events were monitored throughout the study and were similar for IRO-A and IRO tablets. Nausea, headache, abdominal pain, and dizziness were the most common and are consistent with known effects of oxycodone after naltrexone blockade.
Plasma levels of oxycodone in IRO-A tablets were compatible with proportional single-dose pharmacokinetics from 5 to 15 mg under fasted conditions. Administration of IRO-A with food suggested increased overall bioavailability relative to fasting conditions and a reduction in peak systemic exposure of oxycodone that is not expected to be clinically significant. When comparing IRO-A tablets with IRO tablets in the fed state, the overall systemic exposure of oxycodone was comparable, and peak systemic exposure was lower. ClinicalTrials.gov identifier: NCT01530542.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Clinical Therapeutics
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-41, HHS Publication No. (SMA) 11-4658.Accessed November 1, 2011)
- Outpatient prescription opioid utilization in the US, years 2000–2009.http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM220950.pdf(Accessed December 16, 2011)
- RADARS system data indicate immediate release opioids responsible for higher proportion of misuse, abuse and diversion than extended release opioids.RADARS System News. 2009; 4: 1
- Motives, diversion and routes of administration associated with nonmedical use of prescription opioids.Addict Behav. 2007; 32: 562-575
- A profile of OxyContin addiction.J Addict Dis. 2004; 23: 1-9
- Seeking drug treatment for OxyContin abuse: a chart review of consecutive admissions to a substance abuse treatment facility in Kentucky.J Natl Compr Canc Netw. 2003; 1: 423-428
- Route of administration for illicit prescription opioids: a comparison of rural and urban drug users.Harm Reduct J. 2010; 7: 24
- Trends and statistics.Accessed December 16, 2011)
- Oxecta [prescribing information].King Pharmaceuticals, Bristol, TNJune 2011Accessed April 6, 2012)
- Aversion Technology.Accessed April 10, 2012)
- Reducing the abuse potential of controlled substances.Pharmaceutical Medicine. 2010; 24: 21-36
- Intranasal abuse potential of immediate-release oxycodone HCl formulated to deter intranasal abuse (IRO-A).(Poster presented at: 73rd Annual Meeting of the College on Problems of Drug Dependence; June 18–23, 2011; Hollywood, Fla)Accessed April 4, 2012)
- A single-dose, 3-way crossover pharmacokinetic comparison between immediate-release oxycodone hydrochloride with aversion technology (IRO-A, Oxecta), IRO-A with niacin, and oxycodone hydrochloride (Roxicodone) in healthy adults under fasting conditions.Am J Ther. 2012 Feb 18; ([Epub ahead of print])
- ICH Topic E6 (R1) Guideline for Good Clinical Practice.http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf(Accessed April 6, 2012)
- Guidance for industry: food-effect bioavailability and fed bioequivalence studies.http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126833.pdf(Accessed April 16, 2012)Date: December 2002
- Draft guidance on oxycodone hydrochloride.www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM194657.pdf(Accessed April 16, 2012)Date: December 2009
- Noncompartmental Analysis Based on Statistical Moment Theory.in: Pharmacokinetics. 2nd ed. Marcel Dekker, Inc, New York, NY1982: 409
- Transformation and analysis of individual subject ratios.in: Design and Analysis of Bioavailability and Bioequivalence Studies. 2nd ed. Marcel Dekker, Inc, New York, NY2000: 161
- Guidance for industry: statistical approaches to establishing bioequivalence.Food and Drug Administration, Rockville, MdJanuary 2001Accessed April 16, 2012)
- Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products – general considerations.Food and Drug Administration, Rockville, MdMarch 2003Accessed April 16, 2012)
- Statistical methods for average bioavailability.in: Design and Analysis of Bioavailability and Bioequivalence Studies. 2nd ed. Marcel Dekker, Inc, New York, NY2000: 98
- Confidence interval criteria for assessment of dose proportionality.Pharm Res. 2000; 17: 1278-1283
- Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion.Pharm Stat. 2009; 8: 38-49
- Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediate-release oxycodone solution.J Pharm Sci. 1996; 85: 407-410
- Roxicodone [prescribing information].Xanodyne Pharmaceuticals, Inc, Newport, KY2009Accessed April 6, 2012)
- A risk-benefit assessment of naltrexone in the treatment of alcohol dependence.Drug Saf. 1996; 15: 274-282
- Efficacy and tolerability of naltrexone in the management of alcohol dependence.Curr Pharm Des. 2010; 16: 2091-2097
Published online: June 21, 2012
Accepted: May 30, 2012
© 2012 Elsevier HS Journals, Inc. Published by Elsevier Inc. All rights reserved.